About PAVmed
PAVmed is a publicly listed company based in New York (United States) founded in 2014. PAVmed has raised $845 thousand across 13 funding rounds from investors including HHS. The company has 39 employees. PAVmed offers products and services including Lucid Diagnostics and Veris Health. Its focus areas include Diversified Medical Devices, Devices, Life Sciences and Oncology. Its legal entity is PAVmed Inc. Its competitors include Medtronic, GE Healthcare and Boston Scientific; 1 of its 3 listed competitors has raised funding.
Company details
Developer of medical devices and biomarkers to detect various diseases. The products developed by the company include CarpX a minimally invasive device to treat carpal tunnel syndrome, PortIO a novel, implantable, intraosseous vascular access device, and DisappEAR antimicrobial resorbable ear tubes, and many more.
- Headquarters New York, United States
- Employees 39
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website pavmed.com
- Social LinkedIn X YouTube
- Legal Name Pavmed Inc.
- Annual Revenue$71 K (USD)-97.63as on Dec 31, 2025
- Net Profit$401 K (USD)-98.99as on Dec 31, 2025
- EBITDA-$21.7 M (USD)49.87as on Dec 31, 2025
- Total Equity Funding$845K (USD)
in 13 rounds
- Latest Funding Round$30M (USD), Post-IPO
Feb 2026
- Investors
- Employee Count39
Products & Services of PAVmed
PAVmed offers a comprehensive portfolio of products and services, including Lucid Diagnostics and Veris Health.
Provides tests for detecting esophageal precancer.
Offers remote monitoring for personalized cancer care.
Apps and channels of PAVmed
its YouTube channel PAVmed has 262 subscribers and 12 videos.
Videos from PAVmed
The most watched videos on PAVmed's YouTube channel, PAVmed (262 subscribers). Click a video to play it here.
More on PAVmed.
Funding Insights of PAVmed
PAVmed has successfully raised a total of $845K across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $845,000
- Total Rounds 13
- Last Round Post-IPO — $30M
- First Round $845,000
(Nov 2014)
- Investors Count 1
Latest 10 of 13 funding rounds of PAVmed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $30M | Post-IPO | – | – | – |
| Feb 2025 | $2.37M | Post-IPO | – | – | – |
| Jan 2025 | $2.65M | Post-IPO | – | – | – |
| Sep 2024 | $892,112 | Grant | – | – | |
| Aug 2020 | $7.75M | Post-IPO | – | – | – |
| May 2020 | $4.11M | Post-IPO | – | – | – |
| Nov 2019 | $14M | Post-IPO | – | – | – |
| Dec 2018 | $7.75M | Post-IPO | – | – | – |
| Aug 2017 | $500,000 | Post-IPO | – | – | – |
| Jul 2017 | $5M | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in PAVmed
PAVmed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for PAVmed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PAVmed
42 people are tracked at PAVmed (20 in leadership, 14 in board & advisors, 8 in team); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Lishan Aklog | Chairman & Ceo, Co-founder | Leadership |
Shaun O'Neil | Executive Vice President & Chief Operating Officer | Leadership |
Dennis M. Mcgrath | President & Chief Financial Officer | Leadership |
Keren Marshal | Sr. Executive Assistant To Chairman & CEO And General Counsel | Leadership |
Brian Deguzman | Chief Technology Officer And Chief Compliance Officer | Leadership |
Caroline Seely Nederostek | Director | Leadership |
Jim Sykes | Senior Vice President Human Resources | Leadership |
Gisella Lopez | Sr. Director, Clinical Research Operations | Leadership |
Orla McCourt | Director Human Resources Operations | Leadership |
Greg Hummel | Chief Accounting Officer (cao) | Leadership |
Suman Verma | VP Of Molecular Diagnostics | Leadership |
Victoria T. Lee | SVP & Chief Medical Officer | Leadership |
Varun Aggarwal | Vice President, Business Strategy & Development | Leadership |
Jessie Gifford | Senior Director, Product Development & Manufacturing | Leadership |
Peter D. Sleman | Vp, Intellectual Property | Leadership |
Jenna Mowatt | Vp, Marketing & Communications | Leadership |
Deepika Lakhani | Senior Vice President, Chief Regulatory And Quality Officer | Leadership |
Matthieu Ennis | Sr. Director Of Quality | Leadership |
Matt Riley | Senior Director, Investor Relations | Leadership |
David Wurtman, MD | Chief Medical Officer - Lucid Diagnostics | Leadership |
22 more people are available in the full profile.
Complete people profiles for PAVmed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of PAVmed
PAVmed is a publicly listed company on the NASDAQ with ticker symbol PAVM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Apr 2016
- Listed onNASDAQ: PAVM
- Listed entityPAVmed Inc.
- Exchange sectorHealth technology
Timeline of PAVmed
4 dated milestones of PAVmed across 12 years, from founding to its latest funding, stage changes and deals.
- Founded PAVmed is founded.
- Funding First funding round of $845K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $30.0M.
Competitors of PAVmed
PAVmed has 3 listed competitors in our database, 1 of them funded. They include Medtronic, GE Healthcare and Boston Scientific.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| medtronic.com | 1949 | Minneapolis, United States | 1,114 | Medical equipment for treating over 30 chronic diseases is developed. | ||
| gehealthcare.com | 1892 | Chicago, United States | $29.13M | 16,700 | Materials management solutions are provided for healthcare organizations. | |
| bostonscientific.com | 1979 | Marlborough, United States | 63,359 | Wide range of medical devices |
Detailed competitors of PAVmed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PAVmed
The website of PAVmed (pavmed.com) receives about 6.1K visits a month and ranks #5,056,309 among all websites worldwide, #5,834 in Biotechnology and Pharmaceuticals.
- Monthly visits6.1K
▲ 92.4% vs previous month
- Unique visitors1.3K
per month
- Global rank#5,056,309
among all websites
- Category rank#5,834
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.9
- Average visit29 sec
- DevicesDesktop 39% · Mobile 61%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as PAVmed (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pavmed
Complete news archive for PAVmed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PAVmed
PAVmed was founded in 2014.
PAVmed is headquartered in New York, United States. It is registered at New York, New York, United States.
PAVmed is a funded company, having raised a total of $845K across 13 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $5M, raised on Nov 2014.
PAVmed has 39 employees.
Annual revenue of PAVmed is $71K as on Dec 31, 2025.
Developer of medical devices and biomarkers to detect various diseases. The products developed by the company include CarpX a minimally invasive device to treat carpal tunnel syndrome, PortIO a novel, implantable, intraosseous vascular access device, and DisappEAR antimicrobial resorbable ear tubes, and many more.
PAVmed's top competitors include GE Healthcare, Medtronic and Boston Scientific.
PAVmed offers Lucid Diagnostics and Veris Health.
Yes, PAVmed is publicly traded on NASDAQ under the ticker symbol PAVM.
PAVmed has 1 investor. Key investors include HHS.
PAVmed operates through Pavmed Inc..